Navigation Links
Gene-expression signature may signify risk for recurrence, metastasis in prostate cancer
Date:4/15/2013

A team led by Massachusetts General Hospital (MGH) researchers has identified a genetic signature that appears to reflect the risk of tumor recurrence or spread in men surgically treated for prostate cancer. If confirmed in future studies, this finding not only may help determine which patients require additional treatment after the cancerous gland has been removed, it also may help address the most challenging problem in prostate cancer treatment distinguishing tumors that require aggressive treatment from those that can safely be monitored. The report has been issued online in PNAS Early Edition.

"Radical prostatectomy is the standard of care for men whose cancer is advanced but confined to the prostate gland, but we know that the factors we use to determine which patients need radiation therapy after surgery are inadequate," says W. Scott McDougal, MD, of the MGH Department of Urology, corresponding author of the report. "The treatments available to our patients can have significant impact on their quality of life, so a better way to know which patients with localized cancer need additional therapy after surgery and which require no additional treatment is a significant unmet need."

Gene expression signatures indicating patient prognosis and sometimes the most appropriate treatment have been incorporated into care for breast cancer and other tumors. Studies looking for such markers in prostate cancer have had variable results, and their potential usefulness to guide treatment has not been determined. For the current study the research team led by Chin-Lee Wu, MD, PhD, of the MGH Department of Pathology examined samples of malignant tissue from around 200 prostate cancer patients who had radical prostatectomies at the MGH between 1993 and 1995, analyzing the expression patterns of more than 1,500 genes associated with prostate cancer in earlier studies. With the results of that analysis, they developed a 32-gene index to reflect the likelihood that a patient's tumor would recur, signified by detectable levels of prostate-specific antigen (PSA) after the gland had been remove, or spread.

To validate the usefulness of the index, they used it to analyze tissue samples from a different group of almost 300 patients who had their prostates removed in 1996 and 1997, comparing the index with currently used prognostic factors such as PSA levels, physical examination, and a tumor's microscopic appearance to see how accurately each predicted the actual incidence of tumor recurrence or metastasis during the 10 years after surgery. The expression-based index proved to be the most accurate method. Among those it designated as high-risk, the actual incidence of tumor recurrence was 47 percent and of metastasis, 14 percent. Among those classified as intermediate risk, actual recurrence was 22 percent, and metastasis occurred in 2 percent. No recurrence or metastasis were seen in patients classified as low-risk by the gene-expression index.

To get a sense of whether the index could help determine risk at the time of diagnosis, the researchers used it to assess presurgical needle biopsy samples from 79 patients in the validation group. The risk assignment based on biopsy results closely matched the assessment based on surgically removed tissue, and the prognostic ability of the index was better than that of other pathological information available at the time a biopsy was taken. Because the current report is based on study of patients treated at a single institution, the authors note, it requires confirmation in larger, multi-institutional studies.

"A more accurate prognosis at the time of diagnosis could give patients and their physicians much more confidence in choosing a definitive therapy or pursuing active surveillance for those at low risk, which could reduce over-treatment, a critical issue in disease management," says lead author Wu, an associate professor of Pathology at Harvard Medical School. McDougal is the the Kerr Professor of Urology, at HMS.


'/>"/>

Contact: Ryan Donovan
rcdonovan@partners.org
617-724-6433
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
2. URMC researchers connect new genetic signature to leukemia
3. Moffitt researchers identify unique immune gene signature across thousands of patients solid tumors
4. ABC Home & Commercial Services’ Houston Branch Now Offering Discount on Initial Service with Signature Rodent Agreement
5. Personal epigenetic signatures found consistent in prostate cancer patients metastases
6. The Tampa Signature Massage Center Announces Couples Massage Awareness Month
7. The nanomechanical signature of breast cancer
8. Study finds molecular signature for rapidly increasing form of esophageal cancer
9. The Signature Group, Inc. Partners with Alert Logic to Deliver Security and Compliance Solutions
10. For First Time, Pain Signature Spotted on Brain MRIs
11. Excess Pounds Raise Risk of Breast Cancer Recurrence, Death: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... ... Have Dreamed: A Novel of Miracles”: a beautiful and poignant glimpse into the unexpected ... her life. “Who Would Have Dreamed: A Novel of Miracles” is the creation of published ... , Sharon shares that she started her spiritual journey later in life, but mentions, ...
(Date:1/24/2017)... ... 24, 2017 , ... Attention women who want bigger breasts ... autologous fat grafting—taking one’s own fat and putting it in other body part—is ... Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology Surgery & Laser Center, ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... The January ... features a three-year outcome study on how outdoor behavioral healthcare (OBH) – also known ... distress and interpersonal difficulties while experiencing an increased sense of purpose both during and ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The National Council ... for drug and alcohol awareness, have worked with communities to designate the last full ... January 23-29, 2017, the theme is “Shatter the Myths.” As a community, we ...
(Date:1/23/2017)... Jupiter Florida (PRWEB) , ... January 23, 2017 ... ... airing of the highly acclaimed series, Innovations with Ed Begley, Jr., scheduled to ... about the technology behind SmartCap, which was founded in 2008 to address the ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Ahead of today,s trading session, Stock-Callers.com draws investors, attention to ... close: Kite Pharma Inc. (NASDAQ: KITE ), BioPharmX Corp. ... Pharmaceuticals Inc. (NASDAQ: REGN ). According to a report ... 20 th , 2017, down on the day by about 0.5%. ... at: ...
(Date:1/23/2017)... -- A new Transparency Market Research report states that ... US$0.53 bn in 2013 and is predicted to touch US$2.38 bn ... and 2022. The title of the report is "Non-invasive Prenatal Testing ... and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to as non-invasive ...
(Date:1/23/2017)... global  anxiety disorders and depression treatment market  is expected to reach a value ... anticipated to drive the market growth in the coming years. Increasing adoption of ... recent years. Continue Reading ... ... ...
Breaking Medicine Technology: